New combo therapy shows promise for tough bile duct cancer
NCT ID NCT07569679
First seen May 08, 2026 · Last updated May 16, 2026 · Updated 2 times
Summary
This study is for people with bile duct or gallbladder cancer that cannot be removed by surgery. It tests whether adding immunotherapy (adebrelimab) and a targeted drug (apatinib) to a special chemotherapy routine can help patients live longer. About 124 participants will receive either the combination or chemotherapy alone, and researchers will track survival and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Air Force Military Medical University
RECRUITINGXi'an, Shaanxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.